These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12078026)

  • 21. Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C.
    Condat B; Asselah T; Zanditenas D; Estampes B; Cohen A; O'Toole D; Bonnet J; Ngo Y; Marcellin P; Blazquez M
    Eur J Gastroenterol Hepatol; 2006 Mar; 18(3):287-9. PubMed ID: 16462543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How to avoid discontinuation of ribavirin in combination with interferon to maintain efficacy of treatment for chronic hepatitis C patients.
    Kasahara A
    J Gastroenterol; 2004 Nov; 39(11):1125-6. PubMed ID: 15580413
    [No Abstract]   [Full Text] [Related]  

  • 23. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
    Hashimoto Y; Kanto H; Itoh M
    J Dermatol; 2007 Aug; 34(8):577-82. PubMed ID: 17683392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leucopenia is a side effect of combination therapy for hepatitis C infection.
    Russo F; Bacosi M; Miglioresi L; Ricci GL
    Am J Gastroenterol; 2000 Apr; 95(4):1100-1. PubMed ID: 10763981
    [No Abstract]   [Full Text] [Related]  

  • 25. The importance of a prior psychiatric examination in pegylated interferon and ribavirin combination treatment for chronic hepatitis C.
    Kuhara K; Ide T; Uchimura N; Kumashiro R; Arinaga T; Miyajima I; Murashima S; Ogata K; Kuwahara R; Amano K; Fujimoto Y; Sakai K; Ishii K; Morita Y; Shirachi M; Sata M
    Kurume Med J; 2012; 59(3-4):39-44. PubMed ID: 23823013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alopecia universalis as a side effect of pegylated interferon α-ribavirin combination therapy for hepatitis C: a rare case report.
    Verma P; Dayal S; Jain VK; Amrani A
    J Chemother; 2017 Dec; 29(6):380-382. PubMed ID: 27741937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Vogt-Koyanagi-Harada disease associated with interferon-alpha and ribavirin therapy for chronic hepatitis C infection].
    Chebil A; Kort F; Bouraoui R; Youssef NB; El Matri L
    J Fr Ophtalmol; 2010 Mar; 33(3):185-8. PubMed ID: 20172621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cutaneous sarcoidosis during pegylated interferon alpha and ribavirin treatment of chronic hepatitis C--a case report].
    Honsová E; Sticová E; Sperl J
    Cesk Patol; 2007 Jan; 43(1):27-30. PubMed ID: 17370474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon plus ribavirin: a cautionary note.
    Macedo G; Ribeiro T
    Am J Gastroenterol; 1999 Oct; 94(10):3087-8. PubMed ID: 10520894
    [No Abstract]   [Full Text] [Related]  

  • 30. [Depressive symptoms during treatment with interferon alpha for HCV infection--preliminary report].
    Małyszczak K; Inglot M; Pawłowski T; Czarnecki M; Rymer W; Andrzej K
    Psychiatr Pol; 2006; 40(4):799-808. PubMed ID: 17068951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pure red-cell aplasia associated with pegylated interferon-alpha-2b plus ribavirin.
    Miura Y; Kami M; Yotsuya R; Toda N; Komatsu T
    Am J Hematol; 2008 Sep; 83(9):758-9. PubMed ID: 18615552
    [No Abstract]   [Full Text] [Related]  

  • 32. [Pegylated intereferon hematological safety in comparison with standard].
    Fazylov VKh; Manapova ÉR; Tkacheva SV; Sozinova IuM
    Eksp Klin Gastroenterol; 2012; (6):96-9. PubMed ID: 23402198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].
    MMW Fortschr Med; 2002 Sep; 144(38):59. PubMed ID: 12395712
    [No Abstract]   [Full Text] [Related]  

  • 34. Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with Peg interferon alfa-2a and ribavirin.
    Ennaifer R; Cheikh M; Romdhane H; Hefaiedh R; Ben Nejma H; Bel Hadj N
    Tunis Med; 2014 Jan; 92(1):42-3. PubMed ID: 24879173
    [No Abstract]   [Full Text] [Related]  

  • 35. Nephrotoxicity of interferon alfa-ribavirin therapy for chronic hepatitis C.
    Willson RA
    J Clin Gastroenterol; 2002 Jul; 35(1):89-92. PubMed ID: 12080234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C.
    Tinè F; Graviano D; Giannuoli G; Madonia S; Malizia G; Patti S; Fasola S; Cottone M; D'Amico G;
    Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1113-23. PubMed ID: 20848397
    [TBL] [Abstract][Full Text] [Related]  

  • 37.  Pegylated interferon, but not conventional interferon therapy induced severe skin lesions.
    Li Z; Ji F; Zheng Y; An J; Peng Z
    Ann Hepatol; 2012; 11(4):570-1. PubMed ID: 22700642
    [No Abstract]   [Full Text] [Related]  

  • 38. [Probable cutaneous sarcoidosis associated with combined ribavirin and interferon-alpha therapy for chronic hepatitis C].
    Savoye G; Goria O; Herve S; Riachi G; Noblesse I; Bastien L; Courville P; Lerebours E
    Gastroenterol Clin Biol; 2000; 24(6-7):679. PubMed ID: 10962394
    [No Abstract]   [Full Text] [Related]  

  • 39. Paternal use of ribavirin-interferon alpha 2B combination therapy before conception.
    Taguchi N; Ito S
    Can Fam Physician; 2005 Dec; 51(12):1623-5. PubMed ID: 16805078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C].
    Burgueño-Montañés C; Pérez-Álvarez R
    Arch Soc Esp Oftalmol; 2011 Jun; 86(6):193-5. PubMed ID: 21767697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.